Pierre Brissot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pierre Brissot has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Olivier Loréal
National Center of Reference for Rare Genetic Iron Overload Diseases, Pontchaillou University Hospital, Rennes, France
24 shared publications Anne-Marie Jouanolle
National Center of Reference for Rare Genetic Iron Overload Diseases, Pontchaillou University Hospital, Rennes, France
7 shared publications- Edouard Bardou-Jacquet
Univ Rennes, CHU Rennes, service des maladies du foie, F-35000, Rennes, France
7 shared publications Martine Ropert
Inserm-UMR 991, 2, rue Henri-Le-Guilloux, 35033 Rennes, France; CHU Rennes, Department of Specialized Biochemistry, 2, rue Henri-Le-Guilloux, 35033 Rennes, France
7 shared publicationsCaroline Le Lan
6 shared publications- Marie-Bérengère Troadec
Univ Brest, Inserm, EFS, UMR 1078, GGB Brest France
6 shared publications
Latest Publications
- 1 July 2018
- Published by Elsevier in Mutation Research - Reviews in Mutation Research
- Vol. 777, 52-63
Rare anemias due to genetic iron metabolism defects
- 1 July 2018
- Published by Elsevier in Mutation Research - Reviews in Mutation Research
- Vol. 777, 52-63
Rare anemias due to genetic iron metabolism defects
- Top Cited Papers
- 5 April 2018
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 4 (1) , 1-15
Haemochromatosis
Haemochromatosis is defined as systemic iron overload of genetic origin, caused by a reduction in the concentration of the iron regulatory hormone hepcidin, or a reduction in hepcidin–ferroportin binding. Hepcidin regulates the activity of ferroportin, which is the only identified cellular iron exporter. The most common form of haemochromatosis is due to homozygous mutations (specifically, the C282Y mutation) in HFE, which encodes hereditary haemochromatosis protein. Non-HFE forms of haemochromatosis due to mutations in HAMP, HJV or TFR2 are much rarer. Mutations in SLC40A1 (also known as FPN1; encoding ferroportin) that prevent hepcidin–ferroportin binding also cause haemochromatosis. Cellular iron excess in HFE and non-HFE forms of haemochromatosis is caused by increased concentrations of plasma iron, which can lead to the accumulation of iron in parenchymal cells, particularly hepatocytes, pancreatic cells and cardiomyocytes. Diagnosis is noninvasive and includes clinical examination, assessment of plasma iron parameters, imaging and genetic testing. The mainstay therapy is phlebotomy, although iron chelation can be used in some patients. Hepcidin supplementation might be an innovative future approach.
- 5 April 2018
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 4 (1) , 1-15
Top Cited PapersHaemochromatosis
Haemochromatosis is defined as systemic iron overload of genetic origin, caused by a reduction in the concentration of the iron regulatory hormone hepcidin, or a reduction in hepcidin–ferroportin binding. Hepcidin regulates the activity of ferroportin, which is the only identified cellular iron exporter. The most common form of haemochromatosis is due to homozygous mutations (specifically, the C282Y mutation) in HFE, which encodes hereditary haemochromatosis protein. Non-HFE forms of haemochromatosis due to mutations in HAMP, HJV or TFR2 are much rarer. Mutations in SLC40A1 (also known as FPN1; encoding ferroportin) that prevent hepcidin–ferroportin binding also cause haemochromatosis. Cellular iron excess in HFE and non-HFE forms of haemochromatosis is caused by increased concentrations of plasma iron, which can lead to the accumulation of iron in parenchymal cells, particularly hepatocytes, pancreatic cells and cardiomyocytes. Diagnosis is noninvasive and includes clinical examination, assessment of plasma iron parameters, imaging and genetic testing. The mainstay therapy is phlebotomy, although iron chelation can be used in some patients. Hepcidin supplementation might be an innovative future approach.
- Open Access
- 27 March 2018
- Published by Springer Nature in Hepatology International
- Vol. 12 (2) , 83-86
Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype
Although guidelines are available for hereditary hemochromatosis, a high percentage of the recommendations within them are not shared between the different guidelines. Our main aim is to provide an objective, simple, brief, and practical set of recommendations about therapeutic aspects of HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype, based on the published scientific studies and guidelines, in a form that is reasonably comprehensible to patients and people without medical training. This final version was approved at the Hemochromatosis International meeting on 12th May 2017 in Los Angeles.
- 27 March 2018
- Published by Springer Nature in Hepatology International
- Vol. 12 (2) , 83-86
Open AccessTherapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype
Although guidelines are available for hereditary hemochromatosis, a high percentage of the recommendations within them are not shared between the different guidelines. Our main aim is to provide an objective, simple, brief, and practical set of recommendations about therapeutic aspects of HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype, based on the published scientific studies and guidelines, in a form that is reasonably comprehensible to patients and people without medical training. This final version was approved at the Hemochromatosis International meeting on 12th May 2017 in Los Angeles.
- 1 December 2017
- Published by Elsevier in La Presse Médicale
- Vol. 46 (12) , e288-e295
Genetic hemochromatosis: Pathophysiology, diagnostic and therapeutic management
- 1 December 2017
- Published by Elsevier in La Presse Médicale
- Vol. 46 (12) , e288-e295
Genetic hemochromatosis: Pathophysiology, diagnostic and therapeutic management
- Open Access
- 1 March 2017
- Published by Taylor & Francis in International Journal of Clinical Transfusion Medicine
- Vol. ume 5, 1-7
Clinical management of hemochromatosis: current perspectives
Hemochromatosis (HC) corresponds to systemic iron overload of genetic origin. Its spectrum covers HFE-related HC, a frequent disease exclusively present in Caucasians; however, several entities of non-HFE-related HC, which correspond to very rare disorders, have been observed in both Caucasian and non-Caucasian populations. In most HC forms, iron overload is explained by hepcidin deficiency, which increases iron delivery into the plasma from both duodenal and splenic sources, with subsequent organ iron deposition. The diagnosis depends on a noninvasive approach combining clinical, biological, and imaging data. The treatment remains largely based on phlebotomy therapy, which is rarely replaced with erythrocytapheresis or chelation therapy. Hepcidin supplementation represents the logical therapeutics of the future for all HC forms related to hepcidin deficiency.
- 1 March 2017
- Published by Taylor & Francis in International Journal of Clinical Transfusion Medicine
- Vol. ume 5, 1-7
Open AccessClinical management of hemochromatosis: current perspectives
Hemochromatosis (HC) corresponds to systemic iron overload of genetic origin. Its spectrum covers HFE-related HC, a frequent disease exclusively present in Caucasians; however, several entities of non-HFE-related HC, which correspond to very rare disorders, have been observed in both Caucasian and non-Caucasian populations. In most HC forms, iron overload is explained by hepcidin deficiency, which increases iron delivery into the plasma from both duodenal and splenic sources, with subsequent organ iron deposition. The diagnosis depends on a noninvasive approach combining clinical, biological, and imaging data. The treatment remains largely based on phlebotomy therapy, which is rarely replaced with erythrocytapheresis or chelation therapy. Hepcidin supplementation represents the logical therapeutics of the future for all HC forms related to hepcidin deficiency.
- 15 September 2016
- Published by Springer Nature in Environmental Science and Pollution Research
- Vol. 25 (3) , 2007-2013
Hemochromatosis: a model of metal-related human toxicosis
Many environmental agents, such as excessive alcohol intake, xenobiotics, and virus, are able to damage the human body, targeting especially the liver. Metal excess may also assault the liver. Thus, chronic iron overload may cause, especially when associated with cofactors, diffuse organ damage that is a source of significant morbidity and mortality. Iron excess can be either of acquired (mostly transfusional) or of genetic origin. Hemochromatosis is the archetype of genetic iron overload diseases and represents a serious health problem. A better understanding of iron metabolism has deeply modified the hemochromatosis field which today benefits from much more efficient diagnostic and therapeutic approaches.
- 15 September 2016
- Published by Springer Nature in Environmental Science and Pollution Research
- Vol. 25 (3) , 2007-2013
Hemochromatosis: a model of metal-related human toxicosis
Many environmental agents, such as excessive alcohol intake, xenobiotics, and virus, are able to damage the human body, targeting especially the liver. Metal excess may also assault the liver. Thus, chronic iron overload may cause, especially when associated with cofactors, diffuse organ damage that is a source of significant morbidity and mortality. Iron excess can be either of acquired (mostly transfusional) or of genetic origin. Hemochromatosis is the archetype of genetic iron overload diseases and represents a serious health problem. A better understanding of iron metabolism has deeply modified the hemochromatosis field which today benefits from much more efficient diagnostic and therapeutic approaches.
- 25 August 2016
- Published by Springer Nature
- p. 103-112
Iron Overload: Diagnosis, Complications, and Management
- 25 August 2016
- Published by Springer Nature
- p. 103-112
Iron Overload: Diagnosis, Complications, and Management
- 1 February 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , 505-515
Iron metabolism and related genetic diseases: A cleared land, keeping mysteries
- 1 February 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , 505-515
Iron metabolism and related genetic diseases: A cleared land, keeping mysteries
- 1 February 2016
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 200 (2) , 309-325
Hémochromatoses : un monde en pleine mutation
- 1 February 2016
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 200 (2) , 309-325
Hémochromatoses : un monde en pleine mutation
- 16 December 2015
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 10 (3) , 359-370
Optimizing the diagnosis and the treatment of iron overload diseases
(2016). Optimizing the diagnosis and the treatment of iron overload diseases. Expert Review of Gastroenterology & Hepatology: Vol. 10, No. 3, pp. 359-370.
- 16 December 2015
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 10 (3) , 359-370
Optimizing the diagnosis and the treatment of iron overload diseases
(2016). Optimizing the diagnosis and the treatment of iron overload diseases. Expert Review of Gastroenterology & Hepatology: Vol. 10, No. 3, pp. 359-370.